ClinicalTrials.gg
RecruitingNCT06111079Updated Jul 3, 2024

Aspirin Discontinuation in High-Risk Pregnant Women of Preeclampsia

A Phase 3 interventional study of aspirin discontinuation and aspirin continuation in Preeclampsia and Perinatal Haemorrhage, sponsored by FANG HE. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by FANG HE · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,800
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Pre-Eclampsia with a site in China — 12 open to participants now, 13 under way, 2 of them phase 3. Pre-Eclampsia · China.

Planned enrollment
4th of 19
1,800 · median 180
Started
2023
with 3 others
Phase 3
3 of 36
2 open now
Primary completion
2024-12
later than 1 of 12 live
Registered
26th of 36
by date
Lead sponsor
3 of 36
FANG HE

Among the 36 studies in Pre-Eclampsia with a site in China, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 3, reaches primary completion later than 1 of the 12 other live ones, and was the 26th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

12 of the 36 studies in Pre-Eclampsia with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Pre-Eclampsia with a site in China, or all of them as a file.
02

Study summary

Low-dose aspirin (LDA) is considered to be the most effective agent to prevent preeclampsia (PE). At present, there is little exploration about the timing of aspirin discontinuation. Most international guidelines default until 36 weeks of gestation or delivery. China Guideline (2020) recommended that aspirin should be preventively used until 26-28 weeks of gestation, but there was little direct evidence. According to the two-stage theory, placental dysplasia before 28 weeks of gestation is the key to developing PE, the significance of aspirin use after 28 weeks of gestation is debatable. If aspirin discontinuation at 28 weeks of gestation is proven to be feasible for preventing preterm PE, it will not only reduce the risk of Perinatal Haemorrhage but also save medical expenses.

Read the detailed description

This study aimed to optimize the strategy of aspirin to prevent preeclampsia, by exploring whether aspirin discontinuation at 28 weeks of gestation to prevent preterm PE is not inferior to 36 weeks of gestation. We will include pregnant women with normal NT scan who meet at least one high-risk factor or at least two medium-risk factors. During 12-16 weeks of gestation, the mean arterial pressure (MAP) and placental growth factor (PlGF) are measured, then initiating aspirin 100mg qn. At 24-27+6 weeks of gestation, the patients were 1:1 randomly divided into two groups, sFlt-1 and PlGF were detected at the same time. The experimental group discontinue aspirin at 28 weeks of gestation, and the control group receive aspirin until 36 weeks of gestation. The incidence of preterm PE in the two groups was compared by non-inferiority test, and the non-inferiority threshold was 2%.

03

Conditions studied

  • Preeclampsia
  • Perinatal Haemorrhage

Browse trials for

Keywords

  • low dose aspirin
  • prevention
  • preeclampsia
  • pregnancy outcomes
  • randomized controlled trial
  • aspirin discontinuation
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At \<16 weeks of gestation, normal NT scan
  2. At least 1 high risk factor or at least 2 moderate risk factors
  3. Intend to receive prenatal examination and deliver in this institution
  4. Signed a written for participation in the study

Exclusion criteria

Exclusion Criteria:

  1. Aspirin initiated after 16 week
  2. Intolerant or allergic to aspirin
  3. Aspirin adherence was \<80%
  4. Miscarriage or termination of pregnancy before randomization
  5. drop out (do not return to the hospital for delivery).
  6. Lost to follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,800 participants (estimated)

Study arms

  • Experimental
    Aspirin discontinuation group

    initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, discontinuing aspirin at 28 weeks of gestation.

    Drug: aspirin discontinuation

  • Active comparator
    Control group

    initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, receiving 1:1 randomized grouping at 24-27+6 weeks of gestation, continuing aspirin until 36 weeks of gestation.

    Drug: aspirin continuation

Interventions

  • Drugaspirin discontinuation

    Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.

    Also known as: initiation of aspirin in early pregnancy

  • Drugaspirin continuation

    Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.

    Also known as: initiation of aspirin in early pregnancy

06

What researchers measure

Primary outcomes

  1. Incidence of preterm preeclampsia

    delivery with preeclampsia before 37 weeks of gestation

    Time frame: Within one week after delivery

Secondary outcomes

  1. Incidence of early-onset preeclampsia

    delivery with preeclampsia before 34 weeks of gestation

    Time frame: Within one week after delivery

  2. Incidence of term preeclampsia

    delivery with preeclampsia after 37 weeks of gestation

    Time frame: Within one week after delivery

  3. Incidence of gestational hypertension

    new onset of high blood pressure after 20 weeks of gestation (systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg)

    Time frame: Within one week after delivery

  4. Incidence of small for gestational age

    birth weight below the 10th percentile

    Time frame: Within one week after delivery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2024, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 1, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Dec 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06111079
Lead sponsor
FANG HE
Responsible party
FANG HE (Chief Physician/Professor of the Obstetrics Department, The Third Affiliated Hospital of Guangzhou Medical University) — Sponsor-investigator
First posted
Nov 1, 2023
Start date
Nov 1, 2023
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 3, 2024

Study contacts

Fang He, M.D
Contact
hefangjnu@126.com
+86 13724831279
Qingwen Nie, Master
Contact
qw0621n@163.com
+86 15622149953
Fang He, M.D
principal investigator · The Third Affiliated Hospital of Guangzhou Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion